Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: An open-label trial

Journal of Clinical Psychiatry

Volumn 71, Issue 9, 2010, Pages 1247-1249

  Rodriguez, Carolyn I ^a,b   Bender Jr , James ^a   Marcus, Sue M ^a   Snape, Michael ^c   Rynn, Moira ^a,b   Simpson, Helen Blair ^a,b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^c Neuropharm Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONAZEPAM; DESVENLAFAXINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; LISDEXAMFETAMINE; MINOCYCLINE; SERTRALINE; ZOLPIDEM; ANTIINFECTIVE AGENT; SEROTONIN UPTAKE INHIBITOR;

ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; FEMALE; HAMILTON ANXIETY SCALE; HAMILTON SCALE; HUMAN; LETTER; MALE; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME; YALE BROWN OBSESSIVE COMPULSIVE SCALE; DRUG COMBINATION; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; ONSET AGE; PROSPECTIVE STUDY; YOUNG ADULT;

ADULT; AGE OF ONSET; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MINOCYCLINE; OBSESSIVE-COMPULSIVE DISORDER; PROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; YOUNG ADULT;

EID: 77957824537     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09l05805blu     Document Type: Letter

References (21)

1. Pigott TA, Seay SM. A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry. 1999;60(2):101-106. PubMed
2. Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx. 2006;3(1):69-81. doi:10.1016/j.nurx.205.12.06 PubMed (Pubitemid 43276634)
3. Graybiel AM, Rauch SL. Toward a neurobiology of obsessive-compulsive disorder. Neuron. 2000;28(2):343-347. doi:10.1016/S0896-6273(0)013-6 PubMed
4. Coric V, Taskiran S, Pittenger C, et al. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry. 2005;58(5):424-428. doi:10.1016/j.biopsych.205.04.043 PubMed
5. Aboujaoude E, Barry JJ, Gamel N. Memantine augmentation in treatment- resistant obsessive-compulsive disorder: an open-label trial. J Clin Psychopharmacol. 2009;29(1):51-55. doi:10.1097/JCP.0b013e318192e9a4 PubMed
6. Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl). 2006;184(2):254-256. doi:10.107/s0213-05-0246-6 PubMed
7. Stewart SE, Jenike EA, Hezel DM, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(1):34-39. doi:10.1097/JCP.0b013e3181c856de PubMed
8. Feusner JD, Kerwin L, Saxena S, et al. Differential efficacy of memantine for obsessive-compulsive disorder vs generalized anxiety disorder: an open-label trial. Psychopharmacol Bull. 2009;42(1):81-93. PubMed
9. Darman J, Backovic S, Dike S, et al. Viral-induced spinal motor neuron death is non-cell-autonomous and involves glutamate excitotoxicity. J Neurosci. 2004;24(34):7566-7575. doi:10.1523/JNEUROSCI.202-04.204 PubMed
10. Seukeran DC, Eady EA, Cunliffe WJ. Benefit-risk assessment of acne therapies. Lancet. 1997;349(9060):1251-1252. doi:10.1016/S0140-6736(05)6245-2 PubMed
11. Bonelli RM, Hödl AK, Hofmann P, et al. Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol. 2004;19(6):337-342. PubMed doi:10.1097/04850-20410-04 (Pubitemid 39506988)
12. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006-1011. PubMed
13. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56-62. doi:10.136/jnp.23.1.56 PubMed
14. Hamilton M. The assessment of anxiety states by rating. Br Med J Psychol. 1959;32:50-55.
15. Tolin DF, Abramowitz JS, Diefenbach GJ. Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown Obsessive Compulsive Scale. J Clin Psychiatry. 2005;66(12):1549-1557. doi:10.408/JCP.v6n1209 PubMed
16. Fagan SC, Edwards DJ, Borlongan CV, et al. Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol. 2004;186(2):248-251. doi:10.1016/j.expneurol.203. 12.06 PubMed
17. Baptiste DC, Hartwick AT, Jollimore CA, et al. An investigation of the neuroprotective effects of tetracycline derivatives in experimental models of retinal cell death. Mol Pharmacol. 2004;66(5):1113-1122. doi:10.124/mol.104. 01081 PubMed
18. Gibbons RD, Hedeker D, Elkin I, et al. Some conceptual and statistical issues in analysis of longitudinal psychiatric data: application to the NIMH treatment of Depression Collaborative Research Program dataset. Arch Gen Psychiatry. 1993;50(9):739-750. PubMed
19. Bloch MH, Landeros-Weisenberger A, Rosario MC, et al. Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry. 2008;165(12):1532-1542. doi:10.176/api.ajp.208.08020320 PubMed
20. Rosario-Campos MC, Leckman JF, Mercadante MT, et al. Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry. 2001;158(11):1899- 1903. doi:10.176/api.ajp.158.1.189 PubMed
21. Tikka TM, Koistinaho JE. Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol. 2001;166(12):7527-7533. PubMed